11β,17β-dihydroxy-6α,17α-dimethyl-androst-4-en-3-one | 6296-01-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 11β,17β-dihydroxy-6α,17α-dimethyl-androst-4-en-3-one
• 英文别名: 11β,17β-Dihydroxy-6α,17α-dimethyl-androst-4-en-3-on；6-α,17-dimethyl-11β-hydroxytestosterone；11beta,17beta-Dihydroxy-6alpha,17-dimethylandrost-4-en-3-one；(6S,8S,9S,10R,11S,13S,14S,17S)-11,17-dihydroxy-6,10,13,17-tetramethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
• CAS: 6296-01-1
• 化学式: C₂₁H₃₂O₃
• 分子量: 332.483
• InChiKey: LZRQDFQQYIQZLG-YEYOAGGMSA-N

物化性质

• 熔点：
  225-228 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  480.4±45.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  24
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3,3:17,17-bis(ethylenedioxy)androst-5-en-11β-ol 在 四氢呋喃 、 甲醇 、 过氧乙酸 、 乙醚 、 氯仿 、 sodium acetate 、 溶剂黄146 作用下， 生成 11β,17β-dihydroxy-6α,17α-dimethyl-androst-4-en-3-one
  参考文献：
  名称：

  Organic compounds and process

  摘要：

  公开号：

  US02842572A1

文献信息

• TRANSDERMAL ADMINISTRATION OF MENT
  申请人：——

  公开号：US20020012694A1

  公开（公告）日：2002-01-31

  The present invention relates to transdermal dosage forms for delivery of androgens.

  本发明涉及用于递送雄激素的经皮剂量形式。
• ANDROGEN AS A MALE CONTRACEPTIVE AND NON-CONTRACEPTIVE ANDROGEN REPLACEMENT
  申请人：——

  公开号：US20020193359A1

  公开（公告）日：2002-12-19

  The present invention relates to methods of providing male contraception using a specified androgen without the need of a separate sterilizing agent. The invention also describes methods for non-contraceptive androgen replacement and devices useful for carrying out both processes.

  本发明涉及使用指定雄激素提供男性避孕的方法，无需单独的灭菌剂。本发明还描述了用于进行非避孕雄激素替代和实施两种过程的设备的方法。
• Nuclear receptor-mediated introduction of a PNA into cell nuclei
  申请人：——

  公开号：US20030096739A1

  公开（公告）日：2003-05-22

  Disclosed are compositions and methods for introducing Peptide Nucleic Acids (PNAS) into cell nuclei. The PNAs are linked to a ligand that binds a nuclear receptor. The methods have therapeutic and diagnostic applications.

  所公开的是将多肽核酸（PNAS）引入细胞核的组合物和方法。 PNA 与结合核受体的配体相连。 这些方法可用于治疗和诊断。
• Androgen as a male contraceptive and non-contraceptive androgen replacement
  申请人：——

  公开号：US20040132698A1

  公开（公告）日：2004-07-08

  The present invention relates to methods of providing male contraception using a specified androgen without the need of a separate sterilizing agent. The invention also describes methods for non-contraceptive androgen replacement and devices useful for carrying out both processes.

  本发明涉及使用特定雄性激素提供男性避孕的方法，而不需要单独的绝育剂。本发明还描述了非避孕性雄激素替代方法和用于实施这两种过程的装置。
• Transdermal device for administering testosterone or one of the derivatives thereof
  申请人：Sournac Michel

  公开号：US20050100586A1

  公开（公告）日：2005-05-12

  The invention relates to a self-adhesive transdmal device for the administration of testosterone and/or at least one of the derivatives thereof, comprising successively at least one supprt layer, a self-adhesive matrix layer and a detachable protective layer, whereby the matrix layer comprises at least one self-adhesive polymer, at least one formulating adjuvant for the matix layer, at least one solvent chosen from the group made up of solvents of testosterone or the derivatives thereof and testosterone and/or at least one of the derivatives thereof in an oversaturated solution. The device has excellent testosterone permeation qualities and excellent ous tolerance and adhesion qualities. The invention also relates to a method for the production of said device and the use thereof for a mulicament, i.e. within the framework of a testosterone replacement tberapy.

  本发明涉及一种用于给药睾酮和/或其至少一种衍生物的自粘性透皮装置，该装置依次包括至少一个支撑层、一个自粘性基质层和一个可分离的保护层，其中基质层包括至少一种自粘性聚合物、至少一种用于基质层的配制佐剂、至少一种选自睾酮或其衍生物溶剂组的溶剂以及过饱和溶液中的睾酮和/或其至少一种衍生物。该装置具有极佳的睾酮渗透性、良好的耐碱性和粘附性。本发明还涉及一种生产上述装置的方法及其在睾酮替代疗法框架内的多种用途。